Childhood Vaccination: Implications for Global and Domestic Public Health

Neurologic Clinics

Volumn 34, Issue 4, 2016, Pages 1035-1047

  Younger, David S ^a,b   Younger, Adam P J ^c   Guttmacher, Sally ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

Neuroepidemiology; Public health; Vaccination

Indexed keywords

ANTIBODY; BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MEASLES VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; VACCINE; WART VIRUS VACCINE;

COMMUNICABLE DISEASE; DIPHTHERIA; DISEASE CONTROL; HAEMOPHILUS INFECTION; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH ECONOMICS; HEALTH PROGRAM; HEPATITIS B; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFECTION; LEGAL ASPECT; MEASLES; MORBIDITY; MORTALITY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH; REVIEW; ROTAVIRUS INFECTION; RUBELLA; TETANUS; TUBERCULOSIS; VACCINATION; CHILD; DISEASE ERADICATION; GLOBAL HEALTH; IMMUNOLOGY; PROCEDURES;

CHILD; DISEASE ERADICATION; GLOBAL HEALTH; HUMANS; PUBLIC HEALTH; VACCINATION; VACCINES;

EID: 84991822099     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2016.05.004     Document Type: Review

References (39)

1. Largent, M.A., Vaccine. The debate in modern America. 2012, Johns Hopkins University Press, Baltimore (MD).
2. Centers for Disease Control and Prevention (CDC), Ten great public health achievements—United States, 1990-1999. MMWR Morb Mortal Wkly Rep 48 (1999), 241–264.
3. Centers for Disease Control and Prevention (CDC), National, state, and urban area vaccination coverage levels among children aged 19-35 months—United States, 1997. MMWR Morb Mortal Wkly Rep 47 (1998), 547–554.
4. Centers for Disease Control and Prevention (CDC), Ten great public health achievements—United States, 2001-2010. MMWR Morb Mortal Wkly Rep 60 (2011), 619–623.
5. Zhou F. Updated economic evaluation of the routine childhood immunization schedule in the United States. Presented at the 45th National Immunization Conference. Washington, DC, March 28–31, 2011.
6. Vogt, T.M., Wise, M.E., Bell, B.P., et al. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J Infect Dis 197 (2008), 1282–1288.
7. Centers for Disease Control and Prevention (CDC), Ten great public health achievements–Worldwide, 2001-2010. MMWR Morb Mortal Wkly Rep 60 (2011), 814–818.
8. Hussein, I.H., Chams, N., Chams, S., et al. Vaccines through centuries: major cornerstones of global health. Front Public Health, 3, 2015, 269.
9. Lantos, J.D., Jackson, M.A., Harrison, C.J., Why we should eliminate personal belief exemptions to vaccine mandates. J Health Polit Policy Law 37 (2012), 131–140.
10. Available at: www.un.org/millenniumgoals/2015_MDG_Report/pdf/MDG 2015.
11. Plowe, C.V., Vaccine-resistant malaria. N Engl J Med 373 (2015), 2082–2083.
12. Heppner, D.G. Jr., Kester, K.E., Ockenhouse, C.F., et al. Towards an RTS, S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23 (2005), 2243–2250.
13. Jakinovich, A., Sood, S.K., Pertussis: still a cause of death, seven decades into vaccination. Curr Opin Pediatr 26 (2014), 597–604.
14. Mundel, T., Orenstein, W.A., No country is safe without global eradication of poliomyelitis. Editorial. N Engl J Med 369 (2013), 2045–2046.
15. Buttenheim, A.M., Sethuraman, K., Omer, S.B., et al. MMR vaccination status of children exempted from school-entry immunization mandates. Vaccine 33 (2015), 6250–6256.
16. Clemmons, N.S., Gastanaduy, P.A., Fiebelkorn, A.P., et al. Measles—United States, January 4-April 2, 2015. MMWR Morb Mortal Wkly Rep 64 (2015), 373–376.
17. Zipprich, J., Winter, K., Hacker, J., et al. Measles outbreak—California, December 2014-February 2015. MMWR Morb Mortal Wkly Rep 64 (2015), 153–154.
18. Wakefield, A.J., Murch, S.H., Anthony, A., et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351 (1998), 637–641.
19. Wakefield, A.J., Anthony, A., Schepelmann, S., et al. Persistent measles virus infection and immunodeficiency in children with autism, ileo-colonic lymphoid nodular hyperplasia and non-specific colitis. Gut, 42(Suppl 1), 1998, A86.
20. Wakefield, A.J., Montgomery, S.M., Autism, viral infection and measles-mumps-rubella vaccination. Isr Med Assoc J 1 (1999), 183–187.
21. Hooker, B.S., Measles-mumps-rubella vaccination timing and autism among young African-American boys: a reanalysis of CDC data. Transl Neurodegener, 3, 2014, 16.
22. DeStefano, F., Bhasin, T.K., Thompson, W.W., et al. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics 113 (2004), 259–266.
23. Taylor, L.E., Swerdfeger, A.L., Eslick, G.D., et al. Vaccines are not associated with autism: an evidence-based meta-analyses of case-control and cohort studies. Vaccine 32 (2014), 3623–3629.
24. Cawkwell, P.B., Oshinsky, D., Childhood vaccination requirements: lessons from history, Mississippi, and a path forward. Vaccine 33:43 (2015), 5884–5887.
25. Halloran, M.E., Haber, M., Longini, I.M., Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol 136 (1992), 328–343.
26. Farrington, C.P., On vaccine efficacy and reproduction numbers. Math Biosci 185 (2003), 89–109.
27. Magpantay, F.M., Riolo, M.A., de Cellès, M.D., et al. Epidemiological consequences of imperfect vaccines for immunizing infections. SIAM J Appl Math 74 (2014), 1810–1830.
28. Edlefsen, P.T., Leaky vaccines protect highly exposed recipients at a lower rate: implications for vaccine efficacy estimation and sieve analysis. Comput Math Methods Med, 2014, 2014, 813789.
29. Ragonnet, R., Trauer, J.M., Denholm, J.T., et al. Vaccination programs for endemic infections: modelling real versus apparent impacts of vaccine and infection characteristics. Sci Rep, 5, 2015, 15468.
30. Jit, M., Hutubessy, R., Png, M.E., et al. The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Med, 13, 2015, 209.
31. Plotkin, S.A., Vaccines: past, present and future. Nat Med 11 (2005), S5–S11.
32. Leach-Kemon, K., Graves, C.M., Johnson, E.K., et al. Vaccine resource tracking systems. BMC Health Serv Res, 14, 2014, 421.
33. Kim, S.-Y., Goldie, S.J., Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 26 (2008), 191–221.
34. Bloom, D.E., Canning, D., Jamison, D.T., Health, wealth, and welfare. Finance Dev 41 (2004), 10–15.
35. Belli, P.C., Bustreo, F., Preker, A., Investing in children's health: what are the economic benefits?. Bull World Health Organ 83 (2005), 777–784.
36. Bishai, D., Koenig, M., Khan, M., Measles vaccination improves the equity of health outcomes: evidence from Bangladesh. Health Econ 12 (2003), 415–419.
37. Bärnighausen, T., Bloom, D., Canning, D., Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type B vaccine. Vaccine 29 (2011), 2371–2380.
38. Rheingans, R., Atherly, D., Anderson, J., Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness. Vaccine 30 (2012), A15–A23.
39. Verguet, S., Murphy, S., Anderson, B., et al. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. Vaccine 31 (2013), 4902–4910.